LYC 55716Alternative Names: LYC-55716
Latest Information Update: 30 Dec 2016
At a glance
- Originator Lycera
- Class Antineoplastics
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 01 Dec 2016 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT02929862)
- 07 Oct 2016 Lycera plans a phase I/IIa trial for Solid tumours (Second-line therapy or greater, Inoperable/Unresectable) in USA (PO) (NCT02929862)